Compatibility of Recombinant Tissue Plasminogen Activator (rtPA) and Aflibercept or Ranibizumab Coapplied for Neovascular Age-Related Macular Degeneration With Submacular Haemorrhage

British Journal of Ophthalmology - United Kingdom
doi 10.1136/bjophthalmol-2014-306454
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Effects of Intravitreal Gas With or Without Tissue Plasminogen Activator on Submacular Haemorrhage in Age-Related Macular Degeneration

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2007English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Worsening Anatomic Outcomes Following Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Well Controlled With Ranibizumab [Corrigendum]

Clinical Ophthalmology
Ophthalmology
2017English

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study

Ophthalmology
Ophthalmology
2016English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2013English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy